Coherus Oncology (CHRS) News Today $1.16 -0.02 (-1.69%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.17 +0.01 (+0.86%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Stonepine Capital Management LLC Grows Position in Coherus Oncology, Inc. $CHRSAugust 26, 2025 | marketbeat.comCoherus Oncology: On The Shaping UpAugust 25, 2025 | seekingalpha.comCoherus Oncology (NASDAQ:CHRS) Shares Cross Above 200 Day Moving Average - Should You Sell?August 25, 2025 | marketbeat.comNeed To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) RevenuesAugust 10, 2025 | finance.yahoo.comCoherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comCoherus Oncology: Q2 Earnings SnapshotAugust 8, 2025 | sfgate.comCoherus (CHRS) Q2 Revenue Jumps 10%August 7, 2025 | fool.comCoherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comCoherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the companyAugust 7, 2025 | finance.yahoo.comCoherus Oncology (CHRS) Projected to Post Earnings on ThursdayAugust 2, 2025 | marketbeat.comCoherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025July 31, 2025 | globenewswire.comCoherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?July 31, 2025 | marketbeat.comCHRS - Coherus Oncology Inc Key Metrics - MorningstarJuly 11, 2025 | morningstar.comMCoherus Biosciences Receives Nasdaq Deficiency NoticeJuly 3, 2025 | tipranks.comCHRS Coherus Oncology, Inc.June 21, 2025 | seekingalpha.comCoherus Oncology Inc.June 17, 2025 | money.usnews.comBank of America Corp DE Has $212,000 Stock Holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS)June 16, 2025 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Two Sigma Investments LPJune 13, 2025 | marketbeat.comCoherus BioSciences, Inc. (CHRS): A Bull Case TheoryJune 6, 2025 | insidermonkey.comCoherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer TherapeuticsJune 5, 2025 | finanznachrichten.deCoherus BioSciences, Inc. (NASDAQ:CHRS) Director Sells $73,991.12 in StockMay 30, 2025 | marketbeat.comCoherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer TherapeuticsMay 30, 2025 | finance.yahoo.comCoherus To Partner With STORM On Development Of LOQTORZI/STC-15 CombinationMay 29, 2025 | nasdaq.comInsider Selling: Coherus BioSciences, Inc. (NASDAQ:CHRS) Director Sells 99,988 Shares of StockMay 29, 2025 | insidertrades.comCoherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)May 27, 2025 | finance.yahoo.comCoherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdlesMay 23, 2025 | investing.com5,283,292 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by Point72 Asset Management L.P.May 22, 2025 | marketbeat.comStockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to SellMay 22, 2025 | marketbeat.comTang Capital Management LLC Has $5.04 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)May 20, 2025 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Issues Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comCoherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...May 13, 2025 | finance.yahoo.comCoherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comCoherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comCoherus BioSciences (NASDAQ:CHRS) Cut to "Sell" at StockNews.comMay 11, 2025 | marketbeat.comCoherus at The Citizens JMP Life Sciences: Strategic Oncology FocusMay 9, 2025 | investing.comCoherus to Report First Quarter 2025 Financial Results on May 12, 2025May 5, 2025 | globenewswire.comCoherus BioSciences (CHRS) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comXTX Topco Ltd Sells 426,074 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)May 3, 2025 | marketbeat.comCoherus to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comCoherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC WainwrightMay 1, 2025 | marketbeat.comCoherus reports promising cancer treatment resultsApril 29, 2025 | investing.comCoherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric CancerApril 29, 2025 | nasdaq.comCoherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025April 28, 2025 | globenewswire.comBirchview Capital LP Reduces Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)April 28, 2025 | marketbeat.comCoherus Biosciences price target lowered to $1.05 from $1.50 at UBSApril 24, 2025 | markets.businessinsider.comCoherus BioSciences announces CCO Paul Reider’s resignationApril 24, 2025 | uk.investing.comCoherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by StockNews.comApril 17, 2025 | marketbeat.comCoherus BioSciences: Cleaning The Balance Sheet And Developing New DrugsApril 17, 2025 | seekingalpha.comCoherus Biosciences completes divestiture of UDENYCA franchiseApril 14, 2025 | markets.businessinsider.com Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHRS Media Mentions By Week CHRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRS News Sentiment▼1.451.09▲Average Medical News Sentiment CHRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRS Articles This Week▼42▲CHRS Articles Average Week Get the Latest News and Ratings for CHRS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Coherus Oncology and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AnaptysBio News Savara News Sage Therapeutics News Rapport Therapeutics News Kodiak Sciences News Arvinas News Septerna News Gossamer Bio News Zevra Therapeutics News Opthea News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHRS) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts